CooperVision’s latest 1 day multifocal innovation1,2 features Binocular Progressive System™, also found in MyDay® multifocal, for clear vision at all distances and all levels of presbyopia.3
The number of patients with presbyopia is on the rise across the globe, the U.S., and likely in your practice.4-6 In its continued commitment to help improve the way people see each day, CooperVision recently launched its latest innovation in multifocals: clariti® 1 day multifocal 3 Add with Binocular Progressive System™.2
The lens combines new innovations that reflect what patients with presbyopia want in a multifocal contact lens7 and provides even better vision quality*8 and comfort than the original 2 Add design.†8
Here are the Top Five essentials you need to know about the new clariti® 1 day multifocal 3 Add for your patients with presbyopia.
1. Designed with CooperVision Binocular Progressive System®
CooperVision Binocular Progressive System, an innovative 3 Add multifocal system, provides clear vision at all distances and for all levels of presbyopia.3 In fact, Binocular Progressive System offers patients with presbyopia optimal visual acuity at all distances, even as their prescriptions and vision needs change.3
For early presbyopes, the system combines two low Add aspheric center-near designs with a wide distance area and optical progression into the reading area, which is ideal for maintaining clear distance vision when transitioning into multifocal contact lenses.3 For advancing presbyopes, the system combines the wide clear distance vision of the low Add with increasing near support. In the aspheric medium Add design, the central reading area is strengthened and widened.3
2. Enhanced Comfort with Optimized Comfort Edge™
clariti 1 day multifocal 3 Add provides excellent initial comfort on dispensing9 and now features Optimized Comfort Edge design that helps provide a high level of comfort10 for your patients with presbyopia.
In a recent study that enrolled 58 patients at four U.S. clinical sites, the new clariti 1 day multifocal 3 Add met or exceeded the comfort needs of wearers starting on day 1 and surpassed the comfort needs of the original clariti 1 day multifocal wearers.†8
An additional investigation which enrolled 90 patients at a single UK clinical site found that clariti 1 day multifocal 3 Add continued to provide high levels of comfort after 1 week of daily wear11 and was no different than a similarly priced moist multifocal.11
3. Rely on Easy Fits and Refits‡8,12
You can also expect a seamless refit from the original 2 Add optical design8 and with a high fit success rate.12 The simple and highly effective fitting process enables you to efficiently and successfully deliver the right contact lenses to your patients with presbyopia.12 Along with the fitting guide, CooperVision’s OptiExpert™ can assist in your initial lens selection.§
4. Expanded Parameters Offer Greater Rx Opportunities
The new clariti 1 day multifocal 3 Add now offers new, expanded parameters, allowing you to fit even more patients with presbyopia.
Sphere powers are available in +8.00D to -10.00D in 0.25D steps, and -10.50D to -12.00D in 0.50D steps.13
ADD power are available in the following:
- Low (+0.75D to +1.25D)
- Med (+1.50D to +1.75D)
- High (+2.00D to +2.50D)
The expanded parameters in the clariti® 1 day multifocal 3 ADD has the widest range vs. competitor 1-day multifocals, allowing more patients to experience the new lens at an affordable price.2,13
5. Innovations Mean an Even Better Wearing Experience1,8
One study reported that the clariti 1 day multifocal 3 Add provided an enhanced wearing experience compared to the original 2 Add design.*8
New clariti 1 day multifocal 3 Add wearers reported:
- Improved vision compared to the current lens design.*8
- High satisfaction rates for overall comfort‡8 and meeting or exceeding their comfort experience compared with the clariti® 1 day multifocal 2 Add design.†8
- Good overall satisfaction with their new lens-wearing experience. ‡8
Find out more about the new clariti 1 day multifocal 3 Add and help your patients see like they used to.3 Also visit CooperVision’s Online Success Center for additional information and learnings about the new clariti® 1 day multifocal 3 Add.
* Distance logMAR VA -0.05 vs -0.02 (p < 0.01), near VA 0.06 vs 0.11 (p = 0.02) for BPS vs 2 add respectively.
† Days 1 and 13, p<0.05.
‡ Subject rating on a typical day at 2-week visit.
§ Based on retrospective analysis of 26 patients (52 eyes) with subjective refractions ranging between +5.00D to -6.00D and ≤ -1.00 D cylinder.
1. CVI data on file as of May 2023 vs. leading manufacturers.
2. CVI data on file, 2022.
3. CVI data on file, 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 Add; with ratings from 85 to 89 out of 100; n=90 habitual MFCL wearers.
4. Care of the Patient with Presbyopia. American Optometric Association. 2011.
5. Zebardast et al. The Prevalence and Demographic Associations of Presenting Near-Vision Impairment Among Adults Living in the United States. Am J Ophthalmol. 2017;174:134-144.
6. Fricke TR, Tahhan N, Resnikoff S, et al. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia: Systematic Review, Meta-analysis, and Modelling. Ophthalmology. Oct 2018;125(10):1492-1499).
7. CVI data on file 2020. Kubic Online Survey with spherical soft contact lens wearers with presbyopia/symptoms. N= 1005 (555 1 Day, 450 FRP wearers). US, UK, JP; weighted equally.
8. CVI data on file, 2022. Prospective, crossover, bilateral, subject masked, daily wear, dispensing study (4 clinical sites in U.S.) (n=58 habitual soft MFCL wearers).
9. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; with a rating of 93 out of 100; n=90 habitual MFCL wearers].
10. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add with a rating of 88 out of 100; n=90 habitual MFCL wearers
11. CVI data on file, 2021. Prospective, double-masked, randomized, bilateral, one-week cross-over dispensing study with clariti® 1 day multifocal 3 Add and 1-DAY ACUVUE® MOIST MULTIFOCAL; n=90 habitual MFCL wearers.
12. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; n=90 habitual MFCL wearers.
13. CVI data on file 2024. Based on prescription option combinations (sph and add) available across all daily disposable multifocal soft lenses from CVI, JJV, B+L and Alcon in USA Feb 2024.
